Author Correction: ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer

Affiliations

¹ Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
² Center for Advanced Preclinical Research, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
³ Merck KGaA, Biopharma R&D, Translational Innovation Platform Oncology, Frankfurter Street 250, 64293, Darmstadt, Germany.
⁴ Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
⁵ Medical Oncology Branch, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
⁶ EMD Serono Research and Development Institute Inc., Biopharma R&D, Translational Innovation Platform Oncology, Billerica, MA, 01821, USA.
⁷ Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. anish.thomas@nih.gov.

Published Erratum

Christopher W Schultz et al. EMBO Mol Med. 2024 Mar.

. 2024 Mar;16(3):664.

doi: 10.1038/s44321-024-00029-x.

¹ Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
² Center for Advanced Preclinical Research, Leidos Biomedical Research, Inc, Frederick National Laboratory for Cancer Research, Frederick, MD, 21702, USA.
³ Merck KGaA, Biopharma R&D, Translational Innovation Platform Oncology, Frankfurter Street 250, 64293, Darmstadt, Germany.
⁴ Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
⁵ Medical Oncology Branch, National Center for Global Health and Medicine, Tokyo, 162-8655, Japan.
⁶ EMD Serono Research and Development Institute Inc., Biopharma R&D, Translational Innovation Platform Oncology, Billerica, MA, 01821, USA.
⁷ Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA. anish.thomas@nih.gov.

Abstract

ATR inhibition augments the efficacy of lurbinectedin in small-cell lung cancer.
Schultz CW, Zhang Y, Elmeskini R, Zimmermann A, Fu H, Murai Y, Wangsa D, Kumar S, Takahashi N, Atkinson D, Saha LK, Lee CF, Elenbaas B, Desai P, Sebastian R, Sharma AK, Abel M, Schroeder B, Krishnamurthy M, Kumar R, Roper N, Aladjem M, Zenke FT, Ohler ZW, Pommier Y, Thomas A. Schultz CW, et al. EMBO Mol Med. 2023 Aug 7;15(8):e17313. doi: 10.15252/emmm.202217313. Epub 2023 Jul 25. EMBO Mol Med. 2023. PMID: 37491889 Free PMC article.